核心结合因子急性髓系白血病的基因组异质性及其临床意义
该研究对350例成人核心结合因子急性髓系白血病(CBF-AML)进行230个髓系肿瘤相关基因的靶向测序,其中inv(16) 160例、t(8;21) 190例。研究发现两类CBF-AML在协同分子事件上呈现显著多样性,尤其涉及表观遗传修饰基因和黏连蛋白复合物基因,并识别出SRCAP和DNM2等新的候选协作基因突变。Lasso惩罚模型显示t(8;21)、8三体、FLT3及KIT外显子17突变预后较差,而NRAS和WT1突变预后较好,克隆异质性与有利预后相关。
要点
- CBF-AML两类实体在表观遗传和黏连蛋白基因突变谱上高度异质。
- t(8;21)、8三体、FLT3及KIT外显子17突变提示预后较差。
- NRAS、WT1突变及克隆异质性与有利预后相关。
核心结论
- CBF-AML存在显著基因型异质性,特定突变组合与预后相关。
研究设计与样本
- 对350例成人CBF-AML(inv(16) 160例,t(8;21) 190例)进行230个髓系肿瘤相关基因靶向测序。
主要发现
- 除NRAS、KIT、FLT3等信号基因常见突变外,两类CBF-AML在表观遗传修饰和黏连蛋白复合物基因上呈现多样性。
- 识别出SRCAP(总体5%)和DNM2(t(8;21) AML中6%)等新的复发性候选协作基因突变。
- 影响转录和分化的异常发生于较早白血病阶段,先于影响增殖的突变。
- Lasso惩罚模型显示t(8;21)、8三体、FLT3及KIT外显子17突变预后较差,NRAS和WT1突变预后较好。
- 克隆异质性与有利预后相关;按功能分组时,甲基化组基因(DNMT3A、TET2)突变有强负向预后影响。
临床怎么用
- 对CBF-AML患者可考虑扩大基因测序以识别预后相关突变。
- 预后评估需结合t(8;21)、8三体、FLT3、KIT外显子17、NRAS、WT1及甲基化基因突变状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Core-binding factor (CBF) acute myeloid leukemia (AML) encompasses AML with inv(16)(p13.1q22) and AML with t(8;21)(q22;q22.1). Despite sharing a common pathogenic mechanism involving rearrangements of the CBF transcriptional complex, there is growing evidence for considerable genotypic heterogeneity. We comprehensively characterized the mutational landscape of 350 adult CBF-AML [inv(16): n = 160, t(8;21): n = 190] performing targeted sequencing of 230 myeloid cancer-associated genes. Apart from common mutations in signaling genes, mainly NRAS, KIT, and FLT3, both CBF-AML entities demonstrated a remarkably diverse pattern with respect to the underlying cooperating molecular events, in particular in genes encoding for epigenetic modifiers and the cohesin complex. In addition, recurrent mutations in novel collaborating candidate genes such as SRCAP (5% overall) and DNM2 (6% of t(8;21) AML) were identified. Moreover, aberrations altering transcription and differentiation occurred at earlier leukemic stages and preceded mutations impairing proliferation. Lasso-penalized models revealed an inferior prognosis for t(8;21) AML, trisomy 8, as well as FLT3 and KIT exon 17 mutations, whereas NRAS and WT1 mutations conferred superior prognosis. Interestingly, clonal heterogeneity was associated with a favorable prognosis. When entering mutations by functional groups in the model, mutations in genes of the methylation group (ie, DNMT3A, TET2) had a strong negative prognostic impact.
引用
- Jahn N, Terzer T, Sträng E, et al. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020. PMID: 33351131. doi:10.1182/bloodadvances.2020002673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。